Premium
WBC‐reduced platelet concentrates from pooled buffy coats in additive solution: an evaluation of in vitro and in vivo measures
Author(s) -
Van Der Meer Pieter F.,
Pietersz Ruby N.I.,
Tiekstra Margriet J.,
Huijgens Peter C.,
Dekker Wil J.A.,
Reesink Henk W.
Publication year - 2001
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.2001.41070917.x
Subject(s) - platelet , buffy coat , blood product , medicine , in vivo , andrology , centrifugation , platelet concentrate , chemistry , surgery , chromatography , biology , microbiology and biotechnology
BACKGROUND: The use of a platelet additive solution (PAS‐II, Baxter) may have benefits over plasma for storage of platelets. It was the aim of this study to develop a method to produce WBC‐reduced platelet concentrates (PCs) in PAS‐II with >240 × 10 9 platelets and <1 × 10 6 WBCs per unit, which can be stored for 5 days at pH >6.8 and that will give sufficient platelet increments after transfusion: a 1‐hour CCI of >7.5 and a 20‐hour CCI of >2.5. STUDY DESIGN AND METHODS: PCs were made from five pooled buffy coats and 250 g of PAS‐II. After centrifugation the PCs were WBC‐reduced with a filter (Autostop BC, Pall Biomedical) and stored in a 1000‐mL polyolefin container. CCIs were assessed in stable hemato‐oncologic patients after 5‐day old PCs were transfused. RESULTS: Routinely produced PCs contained a median of 310 × 10 9 platelets (n = 5,363) with 3.5 percent containing <240 × 10 9 platelets, in a median volume of 320 mL (n = 11,834). The median number of WBCs was <0.03 × 10 6 (n = 694). The WBC count exceeded 1 × 10 6 in three PCs, but it was always <5 × 10 6 , giving 99‐percent confidence that more than 99.5 percent of the units will contain <1 × 10 6 WBCs. The pH remained >6.8 on Day 8, provided the concentration was below 1.1 × 10 9 platelets per mL (n = 32). After 28 transfusions in 28 patients, the 1‐hour CCI was 12.6 ± 4.3 (mean ± SD, with 2/28 CCIs <7.5) and the 20‐hour CCI was 8.9 ± 5.6 (with 4/28 CCIs <2.5). Limitations of this study include the absence of a control group of patients receiving platelets stored in plasma and of in vivo radiolabeled survival studies, but a comparison of these data with previously published data suggested that the in vivo survival of platelets stored in PAS‐II is less than that of platelets stored in plasma. CONCLUSION: The WBC‐reduced PCs conformed to specifications. These WBC‐reduced PCs could be stored at least 5 days with maintenance of pH, and they gave sufficient increments after transfusion to patients.